|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
18.940 +0.710 (+3.895%) Profitability Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| ROAA (%) | 2.839% | 2.400% | 2.175% | 3.730% | 5.347% |
| ROAE (%) | 7.027% | 5.965% | 5.320% | 8.933% | 12.431% |
| Return on Capital Employed (%) | 4.032% | 3.464% | 3.011% | 5.063% | 7.397% |
Margin Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Gross Profit Margin (%) | 49.877% | 47.774% | 47.646% | 47.115% | 47.947% |
| EBITDA Margin (%) | 19.280% | 16.686% | 12.742% | 13.519% | 17.473% |
| Pre-tax Profit Margin (%) | 12.319% | 10.191% | 7.944% | 10.455% | 15.548% |
| Net Profit Margin (%) | 8.122% | 6.771% | 5.815% | 8.530% | 12.167% |
Liquidity Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Current Ratio (X) | 0.929 X | 0.921 X | 1.001 X | 1.059 X | 1.038 X |
| Quick Ratio (X) | 0.757 X | 0.727 X | 0.778 X | 0.853 X | 0.851 X |
Leverage Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Total Liabilities / Total Assets(%) | 48.505% | 48.991% | 50.121% | 49.532% | 48.179% |
| Total Debt / Total Assets (%) | 30.291% | 30.646% | 30.845% | 28.064% | 27.157% |
| Net Debt / Total Assets (%) | 19.372% | 19.129% | 18.773% | 12.901% | 16.093% |
| Total Debt / Shareholders' Funds (%) | 74.643% | 76.203% | 76.650% | 67.502% | 64.702% |
| Long Term Debt / Shareholders' Funds (%) | 30.620% | 27.498% | 34.076% | 28.844% | 24.777% |
| Net Debt / Shareholders' Funds (%) | 47.737% | 47.565% | 46.650% | 31.031% | 38.341% |
| Net Cash / (Debt) ($) | (23.249B) | (22.461B) | (21.294B) | (13.818B) | (15.006B) |
| Net Cash / (Debt) per share ($) | (8.808) | (8.450) | (7.968) | (5.171) | (5.855) |
| Total Debt / Capital Employed (%) | 43.490% | 44.999% | 43.914% | 40.723% | 39.611% |
| Interest Coverage Ratio (X) | 5.040 X | 3.912 X | 3.473 X | 5.753 X | 8.346 X |
Efficiency Analysis
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Inventory Turnover (Day) | 118.547 Day | 126.388 Day | 121.864 Day | 97.316 Day | 95.945 Day |
| Receivables Turnover (Day) | 76.747 Day | 70.005 Day | 67.610 Day | 56.897 Day | 50.964 Day |
| Payables Turnover (Day) | 48.997 Day | 54.233 Day | 55.056 Day | 47.270 Day | 39.223 Day |
| Remarks: | Real time quote last updated: 25/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,370,562 |
| %Change | 21.686% |
| EPS / (LPS) | RMB 1.270 |
| NBV Per Share (¥) | RMB 18.451 |